Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial.
Michael D HogartyDavid S ZieglerAndrea T FlynnYueh-Yun ChiDenice Tsao-WeiKangning LiuRohan VemuEugene W GernerElizabeth BruckheimerAnasheh ShamirianBeth HasenauerFrank M BalisSusan GroshenMurray D NorrisMichelle HaberJulie R ParkKatherine K MatthayAraz MarachelianPublished in: British journal of cancer (2024)
High-dose DFMO is tolerable when added to chemotherapy in heavily pre-treated patients. A randomized Phase 2 trial of DFMO added to chemoimmunotherapy is ongoing [NCT03794349].
Keyphrases
- high dose
- low dose
- stem cell transplantation
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- acute lymphoblastic leukemia
- study protocol
- peritoneal dialysis
- prognostic factors
- open label
- randomized controlled trial
- phase iii
- squamous cell carcinoma
- multiple myeloma
- mesenchymal stem cells
- patient reported outcomes
- rectal cancer
- patient reported
- cell therapy